WASF2

Across TCGA pan-cancer cohorts, WASF2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated WASF2 data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher WASF2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated WASF2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

PDAC, HNSC, and CCRCC are the cancer types where WASF2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	IV	0.214	0.785	.006	9	view →
HNSC	OS	Tertile	All	1.000	0.925	.013	8	view →
CCRCC	DFS	Median	II,III,IV	0.764	0.490	.013	4	view →
LSCC	OS	Quartile	II,III,IV	0.656	0.917	.045	2	view →
GBM	DFS	Median	All	0.666	0.825	.019	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

WASF2–PDAC (DFS)

Open the PDAC breakdown →